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ABSTRACT 
Purpose: To describe a patient and procedure specific approach to selecting Venous 
thromboembolism (VTE) prophylaxis for men who undergo radical prostatectomy.  
Methods: We performed a literature search and narrative review of VTE after radical 
prostatectomy. We describe the current paradigm of perioperative thromboprophylaxis and 
underlying rationale. Relevant findings from the European Association of Urology 
thromboprophylaxis guidelines are interpreted and summarized.  
Results: The use of extended post-operative thromboprophylaxis for patients who undergo 
radical prostatectomy is appropriate when the risk of symptomatic VTE outweighs the risk of 
major bleeding.  Patient and procedure factors impact VTE risk.  Patient risk can be stratified as 
low, moderate or high based on 4 factors; age >75, BMI>35, VTE in a first degree relative, and 
personal history of VTE.  Procedure risk of VTE and bleeding can be stratified by modality of 
surgery (open, laparoscopic, robotic) and extent of pelvic lymphadenectomy.  Using these 
factors, patients at the lowest risk for VTE will have an expected incidence of VTE of 0.4-0.8% 
and those at highest risk from 1.5-15.7%. Incidence of major bleeding ranges from 0.4-1.4%.   
These ranges emphasize the need to consider the net benefit for each specific patient.  Use of 
mechanical prophylaxis is supported by weaker evidence but has fewer harms and is likely 
reasonable for most patients   
Conclusion: Many patients who undergo radical prostatectomy will benefit from extended post-
operative thromboprophylaxis.  Risk of thrombosis is likely higher with open approach and 
extended lymph node dissection.  The net benefit of treatment should be considered using 
patient- and procedure-specific criteria.  When the net benefit is negligible or possibly harmful 
no pharmacological thromboprophylaxis should be used.   
 
INTRODUCTION 
 Globally, among 185 countries, there will be an estimated 1,276,106 new incident cases 
(3rd highest) and 358,989 cancer-specific mortalities (8th highest) [1, 2]. Each year, more than 
75,000 and 7,000 radical prostatectomies are performed in the United States and the United 
Kingdom [3, 4], respectively, the majority of which are now performed with robotic assistance 
[5]. However, despite improvements in perioperative care, surgical morbidity following 
oncologic operations is still commonplace, including clinical venous thromboembolism (VTE) 
[6-8]. 
 VTE is associated with increased burden of care for patients and society.  VTE in 
oncology patients is associated with a 2.2-fold increase in mortality compared to patients without 
VTE [9]. Prospective cohort studies report that after disease (cancer) progression, VTE is the 
most common cause of death among oncology patients (448 per 100,000 patients) [10].  Data 
from the American College of Surgeons National Surgical Quality Improvement Project 
(NSQIP) report a 30-day readmission rate for patients undergoing radical prostatectomy of 4.1%; 
the most common cause of readmission VTE (13.6% of readmissions) [11]. Furthermore, VTE is 
associated with significant costs for patients and the health care system. Patients with VTE have 
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more hospital admissions (1.07 vs 0.15), emergency room visits (0.31 vs 0.05), and greater total 
cost ($28,353 vs $17,712) compared to patients without VTE [12].  Therefore, there is a need to 
improve perioperative management and reduce the incidence of VTE.  
 There has been considerable evolution in the development of clinical guidelines for 
perioperative VTE prophylaxis. In 2012, the American College of Chest Physicians (ACCP) 
published a comprehensive guideline on thromboprophylaxis including guidelines for patients 
receiving non-orthopedic surgery[13].  The ACCP guideline used robust methodology and the 
GRADE approach. However, this guideline attempted to cover a very large number of surgery 
types using a limited number of guidance statements.  To do so the authors of the ACCP 
guideline committed to a strategy in which the risk of thrombosis would be approximated by a 
catch all category of “abdominal-pelvic” surgery.  This decision imposed a significant limitation 
on the utility of the guideline, since the estimated VTE risk for “abdominal-pelvic” surgery 
required an estimate of the risks across many different procedure types form a number of 
surgical specialties (general surgery, gynecology and urology).  The actual baseline risk of any 
one specific surgery type may frequently not be well represented by this average. For example, 
the risk of VTE after open radical cystectomy is usually not the same as laparoscopic 
prostatectomy[14].  Therefore, the ACCP approach did not account for important surgical factors 
such as surgical approach (laparoscopic/robotic/open) or type of dissection (extent of pelvic 
lymph node dissection). Unfortunately many other available guidelines on prevention of 
perioperative VTE have similar limitations in the approach to determining surgical risk [15].   
A common limitation of many guidelines on VTE prophylaxis is use of an approach that 
stratifies VTE risk by mixing patient and procedure factors in a single score.  Several scoring 
systems have been developed to help stratify preoperative VTE risk in this way, including the 
Pannucci, Rogers, and Caprini scores [16-18]. These scoring systems have been widely used and 
are included in the 2012 ACCP guideline [19]. Briefly, these approaches attempt to generate a 
score based on procedure and patient characteristics which can be used to predict perioperative 
risk of thrombosis. Most data used to generate these scoring systems were not from urological 
surgeries and are therefore indirect.  This is reflected in the types of characteristics included in 
scoring systems which are largely geared toward orthopedic procedures.  For example the risk 
factors of “arthroscopic surgery, immobilizing cast, elective arthroplasty, hip, pelvis or leg 
fracture, acute spinal cord injury within 1 month” from the Caprini system would not typically 
apply to patient who undergo prostatectomy or other urological surgeries. Conversely, Caprini 
may over estimate VTE risk among patients undergoing radical prostatectomy resulting in the 
vast majority being considered high risk.  This is based on the weighting of more general factors 
such as on age, malignancy and major surgery and the resulting risk assessment  does not reflect 
the wide variation on VTE empirically observed in radial prostatectomy populations [14,20]. 
Clinical guidelines should therefor adopt a different approach to account for the impact of 
surgical technique as well as patient characteristics.   
A growing body of evidence supports that VTE risk for patients undergoing radical 
prostatectomy varies by extent of lymph node dissection and surgical approach. In one study, 
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among 773 patients undergoing laparoscopic radical prostatectomy with 90-day follow-up, 
60.8% (n=468) had a concomitant pelvic lymphadenectomy of which 1.5% of patients had a 
VTE, compared to no patients without pelvic lymphadenectomy experiencing a VTE [21]. In an 
analysis of 3,544 patients included in the multi-center LAPPRO trial, 547 patients (15.4%) had a 
pelvic lymphadenectomy, which was associated with an eight-fold greater risk of deep vein 
thrombosis (RR 7.80, 95%CI 3.51-17.32) and six-fold greater risk of pulmonary embolism (RR 
6.29, 95% CI 2.11-18.73) [22]. Additionally, patients without a pelvic lymphadenectomy, who 
underwent an open radical prostatectomy had increased risk of VTE (RR 3.80, 95%CI 1.42-9.99) 
compared to those undergoing robotic radical prostatectomy.  This is also supported by 
systematic reviews of observational data that have described a 2-4fold increase in VTE risk 
among patients who undergo open radical prostatectomy as compared to laparoscopic or robotic 
approaches [20] and an increase in VTE risk with extent of pelvic lymph node dissection. These 
important surgical factors have not been widely incorporated into VTE guidelines which largely 
depend on the aforementioned Caprini, Rogers or Panucci scoring systems to risk stratify 
patients [14].   This lack of face validity in prior guidelines may be one contributing factor for 
low adherence to VTE guidelines among urologists [23,24].  It is likely some of the observed 
variation in practice amongst urologist may reflect the limited availability of patient and 
procedure specific guidance [23,24].  
 
FRAMEWORK FOR LITERATURE SEARCH 
 We performed a Medline search of the period from 1 January 2000 to 30 September 2018 
to identify systematic reviews and guidelines addressing thromboprophylaxis in prostate cancer 
surgery. We focused on incidence and timing of VTE, and bleeding, and evidence for extended 
prophylaxis. The search terms used included radical prostatectomy. robotic assisted radial 
prostatectomy, laparoscopic radical prostatectomy, venous thromboembolism, perioperative 
bleeding, hemorrhage, prophylaxis, thromboprophylaxis, lymph node dissection, alone or in 
combination.   References from review articles and guidelines were also assessed to develop a 
narrative review; specifically, the EAU Thromboprophylaxis guidelines and systematic review of 
thromboprophylaxis for urologic oncology procedures and accompanying references were 
extensively used to provide a narrative for thromboprophylaxis for patients undergoing radical 
prostatectomy. Our search also included a search of society websites for guidelines, in a manner 
similar to a recently published systematic review of guidelines assessing the use 
thromboprophylaxis for urological surgery [15]. 
 
DEVELOPMENT OF GUIDELINES 
 The EAU guidelines for VTE prophylaxis use a different approach to VTE risk 
stratification which we feel is more applicable for patients undergoing urologic procedures [25].  
With respect to radical prostatectomy, these guidelines provide very detailed, evidence-based 
recommendations, which are stratified by patient risk factors, and procedure risk factors 
including surgical approach (open, laparoscopic or robotic) and extent of pelvic lymph node 
5 
 
dissection.  In order to provide guidance at this level of detail a different methodological 
approach was used, which built on previous work by the ACCP [13,19].     
 This new approach centered on generating absolute estimates of baseline risks of VTE 
and bleeding for patients undergoing each urological procedure. In other words, the approach is 
patient and procedure specific.  Estimates of baseline risk were generated by systematic review 
for each outcome of each specific surgery type (i.e. open, laparoscopic or robotic radical 
prostatectomy) and are based on direct evidence from real world data. This represents a kind of 
“natural history” of the incidence of VTE and bleeding for each procedure with no intervention 
to reduce risk.  Knowledge of baseline risk provides urologists with a starting point to judge 
situations in which giving thromboprophylaxis may provide a net benefit.  For instance, for a 
surgery with high baseline risk of VTE and low baseline risk of bleeding, there would be net 
benefit to giving pharmacological thromboprophylaxis.  Conversely, there may be net harm in 
giving pharmacological prophylaxis when a surgery has low baseline risk of VTE and high 
baseline risk of bleeding.   
In general, the tradeoff between VTE and bleeding may also be influenced by patient 
level risk. One important caveat to risk stratification in this framework is that one cannot use risk 
strata that combine patient and procedure risks, since the procedure level risks are already 
accounted for by the baseline risk for each procedure.  For example, a radical prostatectomy will 
always be a pelvic surgery, the patient will always have malignancy, and a number of other 
procedure characteristics will always be present that could impact VTE and bleeding risk 
(duration, positioning, etc…).  For instance, a risk stratification approach that includes the 
predominant patient-level characteristics has been developed and is shown in Table 1. These four 
characteristics were identified by systematic review as the predominant patient-level predictors 
of VTE and the independent relative impact of each factor was estimated [20, 26].  This simple 
approach allows a clinician to judge how the most common patient-level risk factors impact the 
tradeoff of VTE and bleeding when deciding on use of prophylaxis.  For example, if a patient has 
a personal history of VTE, this will increase their baseline VTE risk 4-fold [26].  Consequently, 
this may change the net benefit for use of prophylaxis for a given procedure specific baseline 
risk.   Therefore, very specific patient and procedure-level guidance can be provided with this 
approach.    
To calculate a precise net benefit one must also know the relative effect of the 
intervention used on critical outcomes of symptomatic VTE and major bleeding.  The EAU 
guideline relied on an updated systematic review and meta-analysis of efficacy of heparins 
initially generated by the ACCP.  This updated meta-analysis demonstrated that giving post-
operative pharmacological thromboprophylaxis will decrease the risk of symptomatic VTE by 
50% and increase the risk of major bleeding by 50% [13, 20]. When we apply this relative effect 
of pharmacological prophylaxis to estimates of baseline risk which are stratified by key patient 
factors a net benefit can be calculated for very specific clinical scenarios.  
 With regard to radical prostatectomy, data indicate that VTE and bleeding risk vary by 
surgical approach and extent of pelvic lymph node dissection.  Therefore, the baseline risks of 
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each procedure type (open, laparoscopic, robotic) are calculated separately and pelvic lymph 
node dissection was estimated as an additional procedure-level risk modifier.  Specifically, 
limited/standard pelvic lymphadenectomy doubles the risk of VTE and extended pelvic lymph 
node dissection increases the risk 4-fold compared to no lymph node dissection [21, 27-29]. 
Conversely, limited/standard pelvic lymph node dissection increases bleeding risk by 1.5-fold 
whereas extended pelvic lymphadenectomy increases the risk of bleeding by a factor of 2 
compared to no pelvic lymphadenectomy [20]. In this way each specific patient undergoing a 
radical prostatectomy can be given tailored advice on the risk and benefits of 
thromboprophylaxis (Table 2).   
 
GRADE APPROACH to GUIDELINES 
Different organizations use a variety of systems to evaluate evidence and make 
recommendations.  Increasingly, the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) approach is becoming the standard and has been widely adopted by 
organizations such as EAU, Cochrane collaboration, World health Organization (WHO), 
Uptodate and over 100 organizations internationally [30].  This approach systematically assesses 
the evidence accounting for (i) risk of bias, (ii) inconsistency, (iii) indirectness, (iv) imprecision, 
(v) publication bias(vi) effect size, (vii) dose response, and (viii) confounding [30, 31], which 
allows guideline panelists to describe the quality of evidence that support each recommendation.  
A detailed description is outside the scope of this manuscript, but the goal is to produce 
transparent evidence-based guidelines in a systematic way.  
 It is important to understand the meaning of strong and weak recommendations within 
the GRADE approach in order to correctly interpret guideline statements provided.  Within 
GRADE, strong or weak recommendations are made either for or against a course of action.  
From a patient perspective, strong recommendations usually imply that the vast majority of 
patients in this situation would want to proceed with the recommendation, typically over 90%.  
For the clinician, this is a situation of informed consent in which the patient may decline the 
recommended course but there should be a clear reason for doing so.  Conversely, weak 
recommendations imply that the majority of patient would still want to proceed with the 
recommended course, but a significant proportion may not.  For the clinician this is an 
opportunity for shared decision making, since the “best course” is less clear and therefore the 
decision is more sensitive to patient values and preferences.   
Guideline recommendations may be weak when evidence is strong but the tradeoff is 
close.  Alternatively, benefits or harms may appear large but evidence is weak and therefore less 
certain.  The EAU guideline on thromboprophylaxis made strong recommendations if the net 
benefit was greater than 10 per 1000 and quality was high or moderate.  Weak recommendations 
were made if benefit was 5-10 per 1000 with strong or moderate evidence, or >10 per 1000 but 
with weak or very weak quality evidence.    
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WHO BENEFITS FROM EXTENDED VTE PROPHYLAXIS AFTER RADICAL 
PROSTATECTOMY? 
 The landscape of radical prostatectomy has evolved over the past several decades from a 
primarily open procedure with longer lengths of stay to one that is primarily robotic with 
relatively short lengths of stay.  This has likely changed the relative tradeoffs for VTE and 
bleeding among this patient population.  The 9th edition of the ACCP guidelines recommend that 
most patients who undergo prostatectomy have high VTE risk and would benefit from 4 weeks 
of pharmacological prophylaxis in addition to perioperative compression stocking (sections 3.6.5 
and 3.6.6 of ACCP guideline) [13].  However, this may not adequately reflect the reality of 
contemporary prostate cancer surgery and may result in overtreatment [17, 18].  A new approach 
has been put forward by the EAU which more selectively identified patients who may benefit 
from prophylaxis [25].  A summary of these recommendations are provided in Table 3.   
The question remains: which patients will benefit from extended (4 weeks) VTE 
prophylaxis after radical prostatectomy? To address this Tikkinen et al., conducted simple 
modelling studies that describe the timing of symptomatic VTE and bleeding requiring 
reoperation (Figure 1).  Figure 1 describes the incidence of symptomatic VTE as a linear 
function over the first month.  This means that the risk of developing a symptomatic VTE is the 
same on any one day post-operatively [25, 26].  This is consistent with the observation from 
NSQIP data which demonstrated that among 16,848 patients undergoing radical prostatectomy, 
82.6% of VTEs occurred after hospital discharge [32, 33].  Conversely, major bleeding usually 
occurs soon after surgery with nearly 50% of bleeding events on the day of surgery itself [25, 
26].  Therefore, among patients for whom it is worth giving pharmacological prophylaxis the 
benefit of the intervention occurs after the period of highest bleeding risk, essentially on post-
operative day 1and continues for 28 days.  Consequently, for a given patient who is 
recommended to have thromboprophylaxis, evidence suggests they should receive this starting 
on post-operative day 1 and should continue for 28 days.   
For patients who undergo radical prostatectomy, net benefit is more favorable among 
higher risk patients, with open surgical approach and increasing pelvic lymph node dissection.  It 
is recommended to look up specific recommendations for any one patient pre-operatively at the 
time of discussion with that patient.  In general, patients at any VTE risk strata, who undergo 
open radical prostatectomy regardless of extent of lymph node dissection will benefit from 
extended thromboprophylaxis.  It must be cautioned that the net benefit for use of 
pharmacological prophylaxis with open radical prostatectomy ranges from a borderline value of 
4.5/1000 to a relatively high value of 77/1000 [20].  As such, patient values and preferences may 
vary for some clinical situations and should be addressed when deciding whether to use extended 
prophylaxis.   
In contrast, patients who undergo laparoscopic or robotic prostatectomy the 
determination of net benefit is more sensitive to patient specific risk and extent of lymph node 
dissection.  In this case the majority of patients who undergo laparoscopic or robotic 
prostatectomy without lymph node dissection will not have net benefit from pharmacological 
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prophylaxis.   Only patients with high VTE risk (Table 1) who undergo radical prostatectomy 
with standard lymph node dissection will have net benefit from pharmacological prophylaxis.  
Patients with moderate or high risk of VTE, who have laparoscopic or robotic prostatectomy 
with extended lymph node dissection, will also benefit from pharmacological prophylaxis.   
The use of mechanical thromboprophylaxis has a different magnitude of effect on the 
chief tradeoff of VTE and bleeding. Since bleeding is not thought to be substantially increased 
with this intervention in principle there may be net benefit with lower efficacy at reducing VTE.  
However, it is important to note that studies of mechanical prophylaxis are uniformly low quality 
and therefore estimates of effect are highly uncertain and benefit may be negligible [20, 34].  The 
EAU guideline recommends for the use of mechanical thromboprophylaxis for the majority of 
patients who undergo radical prostatectomy, which is consistent with previous guidelines 
including the 9th edition of the ACCP.  However, this is based on a threshold of net benefit of 
>2.5/1000, which is arguably low from the point of view of some stakeholders.  Potentially this 
can be clarified further with higher quality studies of mechanical thromboprophylaxis.     
There are some limitations to the approach to choosing VTE prophylaxis described.  
Although the approach to patient level risk stratification is pragmatic, there may be additional 
patient-level factors which have not been accounted for.   As additional independent patient level 
factors are identified through systematic review, future iteration of this risk stratification 
approach may be modified accordingly.   Likewise this risk stratification approach has yet to 
validated prospectively.  Future research should aim to validate and refine patient level risk 
stratification.  Likewise, as procedures and perioperative care continues to evolve this may 
impact incidence of adverse events.  Therefore estimates of baseline risk should be revised and 
updated over time to reflect contemporary practice. Additionally, future directions of research 
include evaluation of novel agents such as direct oral anticoagulants (DOAC) for post-operative 
prophylaxis and agents such as tranexamic acid to reduce harms of major bleeding after radical 
prostatectomy.   
 
CONCLUSION 
 Previous approaches to risk stratification of patients who undergo radical prostatectomy 
did not account for important patient and procedure specific characteristics.  Radical 
prostatectomy can be performed by open approach, laparoscopically or robotically with varying 
extent of pelvic lymph node dissection, and these are different surgeries with different risks of 
VTE and bleeding.  A better approach to providing specific advice for our patients evaluates the 
tradeoff between VTE and bleeding for the specific surgery the patient will have.  When the net 
benefit is in favor of thromboprophylaxis then it should be initiated on post-op day 1 and 
continued for 28 days.  When the tradeoff is close or evidence is weak there is less certainty 
about the best course of action. In these situations, it is important to engage our patient in shared 
decision making so that therapies received correspond to patient values and preferences.   
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Table 1: Model for risk of venous thromboembolism according to patient risk factors (Adapted 
with permission [23]) 
 
Risk 
Low Risk No risk factors 1x 
Medium Risk 
Any one of the following: 
• Age ≥ 75 years 
• Body mass index ≥35 kg/m2 
• VTE in first-degree relative (parent, full sibling, child) 
2x 
High Risk • Prior VTE 
• Patients with any combination of ≥2 risk factors 
indicated under Medium risk category 
4x 
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Table 2: The 4-week postoperative risk of symptomatic nonfatal venous thromboembolism and 
bleeding requiring reoperation after radical prostatectomy (Adapted with permission [23]) 
 
 Venous thromboembolism Bleeding requiring reoperation 
Radical Prostatectomy 
Procedure 
Estimate of event 
by patient risk 
strata (%) 
Certainty in 
Estimate 
Estimate of 
event (%) 
Certainty of 
estimate 
Laparoscopic without 
PLND 
Low risk: 0.4 
Medium risk: 0.8 
High risk: 1.5 
Moderate 0.7 Moderate 
Laparoscopic with 
standard PLND 
Low risk: 0.8 
Medium risk: 1.5 
High risk: 3.0 
Moderate 1.0 Moderate 
Laparoscopic with 
extended PLND 
Low risk: 1.5 
Medium risk: 3.0 
High risk: 6.0 
Moderate 1.4 Moderate 
Open without PLND 
Low risk: 1.0 
Medium risk: 2.0 
High risk: 3.9 
Moderate 0.1 Moderate 
Open with standard 
PLND 
Low risk: 2.0 
Medium risk: 3.9 
High risk: 7.9 
Moderate 0.2 Moderate 
Open with extended 
PLND 
Low risk: 3.9 
Medium risk: 7.9 
High risk: 15.7 
Moderate 0.2 Moderate 
Robotic without PLND 
Low risk: 0.2 
Medium risk: 0.5 
High risk: 0.9 
Moderate 0.4 Moderate 
Robotic with standard 
PLND 
Low risk: 0.5 
Medium risk: 0.9 
High risk: 1.9 
Moderate 0.6 Moderate 
Robotic with extended 
PLND 
Low risk: 0.9 
Medium risk: 1.9 
High risk: 3.7 
Moderate 0.8 Moderate 
PLND – pelvic lymphadenectomy 
 
 
  
15 
 
Table 3 Abbreviated summary of EAU recommendations for post-operative VTE prophylaxis 
Surgery Pharmacological  
Prophylaxis 
Mechanical 
Prophylaxis 
 Risk Stata Strength and 
Recommendation 
Strength and  
Recommendation 
Open prostatectomy 
(no PLND) 
Low 
Moderate or High 
Weak for 
Strong for 
Weak for 
Weak for 
Open Prostatectomy 
(standard PLND) 
Low 
Moderate or High 
Weak for 
Strong for 
Weak for 
Weak for 
Open prostatectomy  
(extended PLND) 
All Strong for Weak for 
Robotic or 
laparoscopic 
prostatectomy  
(no PLND) 
Low 
Moderate or high 
Strong against 
Weak against 
Weak against 
Weak for 
Robotic or 
laparoscopic 
prostatectomy  
(standard PLND) 
Low 
Moderate 
High 
Strong against 
Weak against 
Weak for* 
Weak for 
Weak for 
Weak for 
Robotic or 
laparoscopic 
prostatectomy  
(extended PLND) 
Low 
Moderate 
High 
Weak against 
Weak for 
Strong for 
Weak for 
Weak for 
Weak for 
Abbreviations: PNLD, pelvic Lymph node dissection 
*Laparoscopic prostatectomy with PLND showed net benefit of 10 per 1000 but was included 
with robotic prostatectomy to simplify presentation of this table. 
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Figure 1 Cumulative incidence of symptomatic VTE and major bleeding in the first 4 weeks 
post-operatively 
 
 
 
 
Figure 1 modified from: Tikkinen KA, et al. [26]. This is a figure from an Open Access article 
distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly credited. 
